Ignite Creation Date:
2024-05-06 @ 7:59 PM
Last Modification Date:
2024-10-26 @ 3:18 PM
Study NCT ID:
NCT06213831
Status:
RECRUITING
Last Update Posted:
2024-07-12
First Post:
2024-01-10
Brief Title:
A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream
Sponsor:
Incyte Corporation
Organization:
Incyte Corporation
Study Overview
Official Title:
A Maximal Use Trial of Ruxolitinib Cream in Adult Participants With Prurigo Nodularis
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is being conducted to determine the safety and tolerability of ruxolitinib 15 cream under maximal use conditions in participants with Prurigo Nodularis PN
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None